Secukinumab for AS Demonstrates Durable Benefit (CME/CE)

(MedPage Today) -- IL17A inhibitor provides sustained improvement in disease activity and quality of life
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news
More News: General Medicine